Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:gastrointestinal_stromal_tumor
gptkb:FDA advanced systemic mastocytosis |
| gptkbp:ATCCode |
L01EX19
|
| gptkbp:brand |
gptkb:Ayvakit
|
| gptkbp:CASNumber |
1703793-34-3
|
| gptkbp:chemicalFormula |
C26H27F2N5O4
|
| gptkbp:developedBy |
gptkb:Blueprint_Medicines
|
| gptkbp:genericName |
gptkb:avapritinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ayvakit
|
| gptkbp:indication |
gptkb:systemic_mastocytosis
PDGFRA exon 18 mutant GIST |
| gptkbp:legalStatus |
prescription only
Rx-only |
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea edema fatigue cognitive impairment hair color changes |
| gptkbp:target |
gptkb:PDGFRA
gptkb:KIT |
| gptkbp:bfsParent |
gptkb:Blueprint_Medicines
|
| gptkbp:bfsLayer |
7
|